MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s11239-026-03322-3

Медицинская библиотека · Journal of thrombosis and thrombolysis · 2026

Direct oral anticoagulants versus vitamin K antagonists for atrial fibrillation patients on dialysis: A systematic review and meta-analysis of randomized controlled trials and real-world evidence.

Shaheen Omar, Hamdy Mohamed, Afifi Ibrahem Attiya, Hassan Abdelrahman Ahmed, Kassar Omar, Ismail Ahmed, Bedwany Samer Sameh, Elhalawany Badria Atef Ebrahim, Diab Rehab Adel

СтатьяОбзорПеревод в очереди

Аннотация

Atrial fibrillation (AF) is the most common arrhythmia in end-stage renal disease (ESRD) patients on dialysis. These patients face high risks of both thromboembolism and bleeding. Pivotal randomized controlled trials (RCTs) of direct oral anticoagulants (DOACs) excluded these patients, leaving the optimal anticoagulant choice uncertain. We conducted a systematic review and meta-analysis investigating the efficacy and safety of DOACs versus VKAs in AF patients undergoing dialysis. We searched PubMed, Scopus, Web of Science, and Cochrane Library for RCTs and observational studies. Primary outcomes were ischemic stroke, major bleeding, and all-cause mortality. Secondary outcomes included ischemic stroke or systemic embolism, other bleeding events, hemorrhagic stroke, myocardial infarction, and cardiovascular mortality. Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated. Four RCTs and nine observational studies were included in this study, encompassing 31,238 patients. DOACs were associated with significantly lower risk of major bleeding (RR: 0.68, 95% CI [0.49-0.95], I2 = 89.0%), gastrointestinal bleeding (RR: 0.74, 95% CI [0.61-0.90], I2 = 37.1%), and hemorrhagic stroke (RR: 0.23, 95% CI [0.07-0.78], I2 = 1.5%) compared to VKAs. Both groups showed similar risk of ischemic stroke (RR: 0.59, 95% CI [0.32-1.09], I2 = 40.8%), all-cause mortality (RR: 0.85, 95% CI [0.68-1.07], I2 = 73.2%). Other secondary outcomes also showed no significant differences. In AF patients with ESRD receiving dialysis, DOACs provide similar efficacy and lower bleeding risk compared to VKAs. Among DOACs, apixaban appears to offer the greatest net clinical benefit in this population.

Для цитирования: Shaheen Omar, Hamdy Mohamed, Afifi Ibrahem Attiya, Hassan Abdelrahman Ahmed, Kassar Omar, Ismail Ahmed, Bedwany Samer Sameh, Elhalawany Badria Atef Ebrahim, Diab Rehab Adel. Direct oral anticoagulants versus vitamin K antagonists for atrial fibrillation patients on dialysis: A systematic review and meta-analysis of randomized controlled trials and real-world evidence.. Journal of thrombosis and thrombolysis. 2026. DOI: 10.1007/s11239-026-03322-3.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.